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Abstract
Primary percutaneous coronary intervention is the most effective therapy in the management of acute ST Elevation
Myocardial Infarction. Evidence recommends keeping the period from symptom onset to reperfusion to a minimum in
order to preserve left ventricular function, improve outcome and reduce mortality. This position statement describes the
recommendations of the Saudi Arabian Cardiac Intervention Society for optimal conditions and timing for the acute
management of patients presenting with ST Elevation Myocardial Infarction during ordinary and pandemic times.
Keywords: STEMI, PCI, ACS, Transfer, Pandemic

1. Introduction

P

rimary percutaneous coronary intervention
(PPCI) is the most effective therapy in the
management of acute ST Elevation Myocardial
Infarction (STEMI) [1]. Evidence recommends
keeping the period from symptom onset to
reperfusion to a minimum in order to preserve
left ventricular function, improve outcome, and
reduce mortality [2,3,4].
Currently, many hospitals offer PPCI services in
Saudi Arabia. Data from the ﬁrst Saudi Acute

Myocardial Infarction Registry Program showed
that STEMI was the most frequent presentation of
acute myocardial infarction(AMI) and that 29% of
patients received thrombolytic therapy, 45% had
PPCI, 3% had pharmaco-invasive approach while
29% received neither thrombolytic therapy nor
PPCI. Among patients who had PPCI, 65% of men
had a door-to-balloon time (D2BT) of less than
90 minutes whilst only 42% of women were
treated in a timely manner. Additionally, just 5.2%
of all acute coronary syndrome (ACS) patients
utilized an ambulance service to reach a hospital
[5].

Received 8 September 2020; revised 30 October 2020; accepted 1 November 2020.
Available online 18 December 2020
* Corresponding author. Saud AlBabtain Cardiac Center, Dammam, Saudi Arabia.
E-mail address: shukrialsaif@yahoo.com (S. Al Saif).

https://doi.org/10.37616/2212-5043.1210
2212-5043/© 2020 Saudi Heart Association. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

SHA RECOMMENDATION

Transfer of Patients with ST Elevation Myocardial
Infarction for Primary Percutaneous Coronary
Intervention During Ordinary & Pandemic Times
Position statement of the Saudi Arabian Cardiac
Intervention Society

484

JOURNAL OF THE SAUDI HEART ASSOCIATION 2020;32:483e489

SHA RECOMMENDATION

During a Pandemic situation, practice is modiﬁed
to limit the spread and contain the infection.
Transporting a patient with droplet and or airborne
transmitted infection may constitute unacceptable
risk for the team responsible for the transfer without
appropriate personal protective equipment. In
addition implementing appropriate personal protective equipment may cause unacceptable delays
that may result in loss of the expected beneﬁt for the
transfer if this cannot be achieved within the recommended time window [6,7,8,9].
These recommendations have been made
following the GRADE (Grading of Recommendations Assessment, Development and Evaluation)
Working Group. This system was developed and
reﬁned to assess the certainty of evidence of effects
and strength of recommendations [10,11,12]. The
GRADE system classiﬁes the quality of evidence as
high, moderate or low and offers two grades for the
recommendations: Either strong where the desirable effects clearly outweigh the undesirable effects
or weak where the tradeoffs between desirable effects and the undesirable effects are less certain.
Some recommendations are based on expert
consensus. In some situations, performing further
studies is either not possible or unlikely to be clinically worthwhile, thus some recommendations are
based on low or very low-quality evidence. Some of
these recommendations are still given strong status
because of overwhelming consensus among practicing physicians that this is what should be done.
Where there are randomized clinical trials showing
clear beneﬁt from certain treatments or actions
these have been given strong recommendations
status based on high quality evidence.
The recommendations were made in order to set
an acceptable and desirable standard of care for
patients presenting with STEMI. These recommendations should be used by practicing physicians as
well as policy makers, hospital administrators as
well as payers for healthcare to inform on the expected safe standards supported by best available
evidence and that are applicable to practice conditions in Saudi Arabia. We relied on full text and
abstract publications in English language in Pub
Med. We also searched abstracts from the Saudi
Heart Association meetings including the terms;
STEMI transfer, PPCI, STEMI network and thrombolysis for STEMI.

2. Patient transfer for primary PCI versus onsite thrombolytic therapy
The Prospective Codi IAM network multi-center
STEMI registry collected data from non- PCI
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capable centers. Thirty-day mortality of patients
who had thrombolysis among those whose symptom onset to ﬁrst medical contact (FMC) was less
than 120 minutes was worse compared to those who
were transferred to a PCI capable center with
symptom onset to FMC less than 140 minutes.
Although door to needle time (D2NT) was relatively
long in the study, the mortality rate was 2% amongst
patients treated in less than 99 minutes by PPCI in
comparison to 7.7% in patients who received
thrombolytic therapy [13].
In the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with The
Guidelines (ACTION-GWTG), 33,901 STEMI patients who were transferred for PPCI were studied.
26510 patients (78.2%) were transferred directly to
a catheterization laboratory while 7,391 (21.8%)
were transferred ﬁrst to a hospital's emergency
department. Compared with patients transferred
to an emergency department, STEMI patients who
were transferred to a cardiac catheterization unit
had signiﬁcantly lower ﬁrst D2BT (median 191
versus 116 minutes, P < 0.0001). This was associated with lower mortality with a hazard ratio of
0.58 [14].
Current guidelines and practice are based on nonpandemic situations. During the current COVID-19
pandemic there is overwhelming concern for the
potential for spreading infection from areas where
the infection is prevalent to other areas. In addition,
the risk for the transfer team may be quite high
without strict adherence for wearing personal protective equipment according to infection control
recommendations. What has been observed in cardiac catheterization units is that implementing
appropriate personal protective equipment results
in delays of patients reaching the unit in a timely
manner. Under these circumstances many have
advocated using thrombolytic therapy unless there
are contraindications [6,7,8,9].

Performing polymerase chain reaction testing for
the SARS-CoV-2 virus before transfer of patients
from one hospital to another is not practical for
PPCI because of the time it takes to take the swab
and to perform and obtain the result. However
testing, where available, is advisable for patients
who are treated by thrombolytic therapy in order to
give patients with negative polymerase chain reaction result the beneﬁt of transferring them within
the ﬁrst 24 hours for subsequent PCI.

3. Evidence on the safety of transfer
Transferring patients up to 120 km from a non PCI
hospital to a PCI center was found to be safe,
resulting in lower 30-day mortality in comparison to
thrombolytic therapy particularly if symptom onset
was more than 3 hours [15]. In the Trial of Routine
Angioplasty and Stenting after Fibrinolysis to
Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) pilot study, no complications occurred during transfer to PCI centers [16].
One very high risk subgroup is patients with STEMI
and cardiogenic shock. This group accounts for signiﬁcant in-hospital and post discharge mortality in
STEMI patients. Every effort should be made to
improve the survival of these patients, as the number
needed to treat to save one additional life is low. [17].
The German prospective multicenter feedback
intervention and treatment times in STEMI trial
(FITT-STEMI) analyzed raw time data to calculate
the interval between FMC and balloon inﬂation. [17]
Categorical outcomes were compared between four
groups. 12,675 STEMI patients received emergency
medical services transportation (EMS) and treated
with primary PCI, whereas 10,776 patients (85%)
had no pre-hospital resuscitation and reached a PCI
hospital in stable condition. A total of 1,200 patients
(9.5%) had out of hospital cardiac arrest, 369 patients had stable condition and 831 patients had
cardiogenic shock at the PCI hospital. 699 patients
had cardiogenic shock without out of hospital
cardiac arrest. This latter group derived maximum
beneﬁt from early primary PCI with a number
needed to treat of 5 to save one life. A particular
high risk of death was observed in patients with
contact to balloon time from 150 to 180 min, with
20% mortality after PCI. For contact to balloon time
ranging from 60 to 180 min, they found a nearly
linear relationship between treatment time and
mortality in all the groups. Every 10-min treatment
delay resulted in 3.31 additional deaths in 100 PCI
treated cardiogenic shock patients with no out of
hospital cardiac arrest. The most recent European
Society of Cardiology Guidelines recommend the
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maximum expected delay between FMC and
primary PCI should be considered as the essential
time target for clinical decision and the quality
metric for care delivery, and not just the in-hospital
D2BT. [2] The D2BT has been extensively used as a
quality measure of in-hospital processes. The FITTSTEMI trial indicated strong impact of contact to
balloon time on in-hospital mortality in patients
with cardiogenic shock and or out of hospital cardiac arrest and shows that 90 minutes should be the
target [17].
A strategy of bundled care including direct
transfer of STEMI patients for PPCI was implemented in Makkah during the Hajj season and was
found to signiﬁcantly reduce cardiovascular disease
speciﬁc mortality from 53.2% in 2008 to 16.7% in
2011. Pharmaco-invasive strategy was the primary
re-perfusion approach when primary PCI could not
be offered in a timely manner [18].

4. Transfer back to local hospital
In the Transfer AMI pilot study, patients were
returned back to their community hospital without
any clinical event of note [16]. In a study in Oslo on
patients with ACS, a fast-track approach was
compared to ordinary care and found that up to 95%
could be returned safely the same day after PCI to
their referring hospital [19].
In a study at Prince Sultan Cardiac Center Qassim, stable patients without complications during
PCI procedure were returned to the referring hospital immediately following the PPCI. The transfer
back was with the agreement of the local hospitals.
The local hospital could provide adequate care for
patients with acute myocardial infarction following
revascularization. In a series of 124 patients
returned following primary PCI, one patient had AV
block and one patient developed a right arm hematoma and was managed conservatively. No other
adverse events were encountered during the
ambulance journey or up to 30 days [20].

5. SACIS recommendations
5.1. General recommendations
Programs to improve public health awareness
regarding when to seek medical advice (Strong
Recommendation, Low-Quality Evidence) [5,21].
Improve healthcare workers awareness of importance of timely evaluation, therapy and urgent
transportation for patients with symptoms of acute
coronary syndrome (Strong Recommendation,
Moderate-Quality Evidence) [22].
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Establish formal protocols and communication
networks between all clinics and hospitals with no
PCI capability with primary PCI facilities. A champion is required for each facility participating in a
primary PCI network (Strong Recommendation,
Moderate-Quality Evidence) [2,3,4,23].
The impact of early primary PCI is greatest in
patients with cardiogenic shock with or without outof-hospital cardiac arrest (Strong Recommendation,
Moderate-Quality Evidence) [17].
Hospitals with PCI capability should facilitate
accepting transferred patients with STEMI from
non-PCI capable hospitals with direct transfer to the
cardiac catheterization unit following a non-refusal
principle (Strong Recommendation, ModerateQuality Evidence) [14].
Referring hospitals with cardiology service should
take back patients after primary PCI when required
upon interventional cardiologist recommendation
(Strong Recommendation, Moderate-Quality Evidence) [19,20].
5.2. Recommendations for hospitals without PCI
facilities (Fig. 1)
The diagnosis of STEMI is clinically conﬁrmed
with an ECG within 10 minutes from presentation
(Strong Recommendation, Low-Quality Evidence)
[2,3,4].

The decision for transfer should be made by the
ﬁrst medical contact (Strong Recommendation,
Moderate-Quality Evidence) [13,14].
Patients should be loaded with 162-325 mg
Aspirin, P2Y12 inhibitors (preferably Ticagrelor
180 mg or clopidogrel 600 mg when the former is
not available or contraindicated and 60 units per
kilogram (maximum dose 4000 units) intravenous
un-fractionated heparin in the referring hospital or
clinic within the ﬁrst 10 to 15 minutes from presentation (Strong Recommendation, High-Quality
Evidence) [2,3,4].
During Pandemic situation thrombolytic therapy
should be administered in the emergency room
within the ﬁrst 30 minutes of arrival if no contraindications exist. PPCI may be considered if thrombolytic therapy is contraindicated, not available or
patient presents beyond the 12-hour window. Rescue
PCI may be considered for those that do not show
evidence of re-perfusion. The greatest concern associated with transfer is infection to healthcare workers
and other patients. Because of this, transfer of patients’ needs to be limited. If transfer is deemed
necessary then adequate protection of staff must be
ensured. Transfer should be considered for patients
with cardiogenic shock without out of hospital cardiac
arrest and to those with contraindications for
thrombolytic therapy. If polymerase chain reaction
testing is available then routine testing and obtaining

Fig. 1. Arrival to Non-PCI Facility.
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Fig. 2. Arrival to PCI Facility.

the result urgently is appropriate for patients who are
given thrombolytic therapy (Strong Recommendation, Moderate-Quality Evidence) [6,7,8,9].
Patients must be continuously monitored once
STEMI is conﬁrmed with a functioning deﬁbrillator
attached (Strong Recommendation, Low-Quality
Evidence) [2,3,4].
All staff attending the patient must be ACLS
certiﬁed (Strong Recommendation, Low-Quality
Evidence) [2,3,4].
The process of transfer between facilities must
include ACLS certiﬁed staff (physicians, paramedics
or nurses) and a monitor deﬁbrillator (Strong
Recommendation, Low-Quality Evidence) [2,3,4].
The door-in-door-out time must not exceed
30 minutes (Strong Recommendation, Low-Quality
Evidence) [13,14,15,16,17].
Transfer of patients should be directly to the
catheterization lab in the receiving hospital
bypassing the emergency room (Strong Recommendation, Moderate-Quality Evidence) [14].
The benchmark from ﬁrst medical contact to device
time should not exceed 120 minutes (Strong Recommendation, Moderate-Quality Evidence) [13,17].
The benchmark from arrival to the primary
PCI facility to device time should not exceed 60 minutes (Strong Recommendation, Moderate-Quality
Evidence) [24].

If patients cannot be transferred within ﬁrst
medical contact to device time of less than 120 minutes, these patients must receive thrombolytic
therapy (if no contraindications) at the non-PCI facility with door-to-needle time of less than 30 minutes (Strong Recommendation, Moderate -Quality
Evidence) [2,3,4,13].
5.3. Recommendations for hospitals with PCI
facilities (Fig. 2)
The diagnosis of STEMI is clinically conﬁrmed
with an ECG within 10 minutes from presentation
(Strong Recommendation, Low-Quality Evidence)
[2, 3,4].
The cardiac catheterization unit should be activated by the ER physician (Strong Recommendation, Low-Quality Evidence) [2,3,4,22].
Patients should be loaded with 162-325 mg
Aspirin, P2Y12 inhibitors (preferably Ticagrelor
180 mg or clopidogrel 600 mg when the former is
not available or contraindicated and 60 units per
kilogram bodyweight (maximum dose 4000units)
intravenous un-fractionated heparin within the ﬁrst
10 to 15 minutes from presentation (Strong
Recommendation, High Quality Evidence) [2,3,4].
Patients must be continuously monitored once
STEMI is conﬁrmed with a functioning deﬁbrillator
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attached (Strong Recommendation, Low Quality
Evidence) [2,3,4].
All staff attending the patient must be ACLS
certiﬁed (Strong Recommendation, Low Quality
Evidence) [2,3,4].
Transfer to the catheterization lab by an ACLS
certiﬁed physician and nurses and a monitor deﬁbrillator and with adequate personal protective
equipment protection for the transfer team during
pandemic times. The transfer as well as the transfer
route must comply with relevant local infection
control recommendations to ensure safety of patients as well as all healthcare workers (Strong
Recommendation,
Low
Quality
Evidence)
[2,3,4,6,7,8,9].
The benchmark from ﬁrst medical contact to device time should not exceed 90 minutes, unless
symptom onset was less than two hours. In this case,
ﬁrst medical contact to device time should not
exceed 60 minutes (Strong Recommendation, Moderate Quality Evidence) [2,3,4,24].
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